Abstract:Abstract Noncoding mutations in the cancer genome have historically been poorly understood. Recent studies have shown however that mutations in intergenic regions may play an important role in cancer by introducing de novo regulatory elements and thus cis-regulating target gene expression. While mono-allelic expression of the dysregulated gene is an important signature of regulatory noncoding mutations, recognition of this feature has not been implemented by any methods evaluating noncoding mutations to date. To perform genome-wide detection of noncoding mutations with a potential regulatory function, we developed a novel computational approach implementing this allelic specific expression signature (ASE) as a core component, using WGS and RNAseq data as input. We first searched for genes showing ASE across the tumor genome by comparing the minor allele frequency of heterozygous markers between WGS and RNAseq data. We excluded genes known to be in an imprinted locus, as well as sites matching a precomputed set of 5,576,857 problematic polymorphism markers (estimated by analyzing WGS data from 625 normal genomes). Next, the somatic mutations were filtered for regulatory candidates that could introduce a transcription factor (TF) binding motif absent from the reference sequence. We included 614 TF binding motifs from the HOCOMOCO database and performed motif analysis with the FIMO package. Finally, the somatic mutations were assigned to dysregulated genes in the same topologically associating domains in human defined by public Hi-C data and prioritized by open chromatin state defined by DNaseI hypersensitivity regions (ENCODE project). We applied our approach to 22 T-ALL tumor samples collected at Shanghai Children’s Medical Center in a pilot study consisting of 13 diagnosis and 9 relapse samples (9 of these were trios). WGS was performed on both tumor and normal samples and RNAseq was performed for the tumor sample only. We predicted 213 regulatory noncoding mutations (157 unique variants) in total from this cohort, potentially targeting 119 genes. Among the dysregulated targets we found TAL1 and LMO2, which are known TFs playing a key role in T-ALL. TAL1 mutations were identified in a total of 6 tumors (3 trios). Besides the known oncogenic insertion at ~7kb upstream of TAL1 (1 trio), we also discovered a novel mutation in the first intron of TAL1 (2 trios) that may potentially drive ectopic TAL1 expression. Novel LMO2 mutations were found in 6 tumors (3 trios) at 3 different sites. This approach also identified novel targets such as GPSM1 and PTPRN2, shedding light on heretofore unknown players in T-ALL targeted by noncoding mutations. By integrating WGS and RNAseq data, our novel computational framework can identify somatic noncoding mutations in cancer that may introduce de novo regulatory elements, thus driving target gene expression. Wider application of this approach will expand our understanding of the role of noncoding mutations in the cancer genome. Citation Format: Yu Liu, Michael Edmonson, Xiaotu Ma, Michael Rusch, Yongjin Li, Benshang Li, Shuhong Shen, A. Thomas Look, Jinghui Zhang. Computational approach for discovery of regulatory noncoding variants in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1574. doi:10.1158/1538-7445.AM2017-1574

Sequence-to-expression approach to identify etiological non-coding DNA variations in P53 and cMYC-driven diseases

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

Integrated Multi‐omics Data Analyses for Exploring the Co‐occurring and Mutually Exclusive Gene Alteration Events in Colorectal Cancer

Identification of synonymous pathogenic variants in monogenic disorders by integrating exome with transcriptome sequencing

Long-read DNA and cDNA sequencing identify cancer-predisposing deep intronic variation in tumor-suppressor genes

Abstract 1574: Computational Approach for Discovery of Regulatory Noncoding Variants in Cancer

Exploring the Role of Non-synonymous and Deleterious Variants Identified in Colorectal Cancer: A Multi-dimensional Computational Scrutiny of Exomes

SETD8C302RMutation Revealed from Myofibroblastoma-Discordant Monozygotic Twins Leads to P53/p21 Deficit and WEE1 Inhibitor Sensitivity

Multiple Gene Dysfunctions Lead to High Cancer-Susceptibility: Evidences from a Whole-Exome Sequencing Study.

Identifying somatic fingerprints of cancers defined by germline and environmental risk factors

Exploring the genetic and epigenetic underpinnings of early-onset cancers: Variant prioritization for long read whole genome sequencing from family cancer pedigrees

Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

Allelic Expression of Deleterious Protein-Coding Variants Across Human Tissues

Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers

Defining the function of disease variants with CRISPR editing and multimodal single cell sequencing

Identification of a novel 5-methylcytosine-related signature for prognostic prediction of kidney renal papillary cell carcinoma and a Putative target for drug repurposing

Comprehensive characterization of protein–protein interactions perturbed by disease mutations

Abstract 6085: Leveraging targeted epigenetic and genetic detection for cost-effective cancer classification

Promoter Deletion Leading to Allele Specific Expression in a Genetically Unsolved Case of Primary Ciliary Dyskinesia

"Druggable" Alterations Detected by Ion Torrent in Metastasis Colorectal Cancer Patients

Explainable models using transcription factor binding and epigenome patterns at promoters reveal disease-associated genes and their regulators in the context of cell-types